Vedolizumab is a monoclonal antibody developed by Millennium Pharmaceuticals, Inc (a subsidiary of Takeda Pharmaceuticals) for the treatment of ulcerative colitis and Crohn's disease.It binds to integrin α4β7 (LPAM-1, lymphocyte Peyer's patch adhesion molecule 1).Blocking the α4β7 integrin results in gut-selective anti-inflammatory activity.It is marketed under the trade name Entyvio.
Related Products:
Alirocumab; Denosumab; Eculizumab; Evolocumab; Omalizumab; Ustekinumab; Trastuzumab; Omalizumab; Nivolumab; Denosumab; Cetuximab; Bevacizumab; Aflibercept